Literature DB >> 31289564

Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α-Gal epitopes.

Xiaowei Xing1, Zhenyu Zou2, Changzheng He1, Zilong Hu1, Kai Liang1, Wentao Liang1, Yufeng Wang3, Xiaohui Du1.   

Abstract

Colorectal cancer (CRC) is one of the most common types of gastrointestinal malignancy. Traditional therapeutic options for CRC exhibit a limited effect. Adoptive cellular therapy has emerged as a new treatment strategy for CRC. Dendritic cells (DCs) are potent antigen-presenting cells. Specific cytotoxic T lymphocytes (CTLs) activated by DCs pulsed with tumor lysate have been reported to be a safe and promising treatment approach for CRC. However, the antitumor effect of specific CTLs remains limited. The low immunogenicity of tumor-associated antigens (TAAs) is the main reason for this limited therapeutic effect. In the present study, α-gal epitopes were synthesized on the CRC cell line SW620 to increase the immunogenicity of TAAs. DCs were pulsed with α-gal-expressing tumor lysate and CTLs were activated by these DCs. The cytotoxicity of CTLs was measured in vitro. The results demonstrated that DCs pulsed with α-gal-expressing tumor lysate can increase the frequency of CD3+CD8+ CTLs and natural killer T cells, increase the level of tumor necrosis factor-α produced by CTLs and enhance the cytotoxicity of CTLs against tumor cells. Therefore, this novel approach may be an effective treatment strategy for patients with CRC.

Entities:  

Keywords:  CRC; DC; TAA; cytotoxic T cell; immunogenicity; α-gal epitopes

Year:  2019        PMID: 31289564      PMCID: PMC6546984          DOI: 10.3892/ol.2019.10376

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  3 in total

1.  CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy.

Authors:  Juan Zhang; Lei Wang; Shuyi Li; Xuefeng Gao; Zhong Liu
Journal:  Cancer Cell Int       Date:  2022-06-17       Impact factor: 6.429

Review 2.  Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.

Authors:  Ling Ni
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

Review 3.  Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.

Authors:  Cristina Aparicio; Marina Belver; Lucía Enríquez; Francisco Espeso; Lucía Núñez; Ana Sánchez; Miguel Ángel de la Fuente; Margarita González-Vallinas
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.